^
    over4years
    [VIRTUAL] Development of APG-3526 as a novel and highly efficacious MCL-1 inhibitor (AACR-II 2020)
    In conclusion, we have developed a novel and highly potent MCL-1 inhibitor, APG-3526, which displays clinically relevant pharmacokinetic properties and elicits potent antiproliferative and antitumor activities via disrupting MCL-1 complex and triggering caspase activation, especially in MCL-1 driven MM models. These results support APG-3526 as a promising MCL-1inhibitor for further clinical development.
    PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
    |
    APG-3526